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Background: Because neuroprotective effects of estrogen remain controversial, we aimed to investigate the
effect of different doses of estradiol (E2) on cerebral ischemia using both in vivo and in vitro experiments.
Results: PC12 cells were cultured at physiological (10 nM and 20 nM) or pharmacological (10 μM and 20 μM) dosages
of E2 for 24 hours (h). The results of 5-bromodeoxyuridine (Brdu) incorporation and flow cytometric analysis showed
that physiological doses of E2 enhanced cell proliferation and pharmacological doses of E2 inhibited cell proliferation.
After the cells were exposed to oxygen and glucose deprivation (OGD) for 4 h and reperfusion for 20 h, the results of
3-(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyl tetrazolium bromide (MTT) assay, lactate dehydrogenase (LDH) release assay,
flow cytometric analysis and Western blot analysis showed that physiological doses of E2 enhanced cell viability,
reduced cell apoptosis and decreased the expression of pro-apoptotic protein caspase-3. In contrast, pharmacological
doses of E2 decreased cell viability and induced cell apoptosis. In vivo, adult ovariectomized (OVX) female rats received
continuous subcutaneous injection of different doses of E2 for 4 weeks. Transient cerebral ischemia was induced for
2 h using the middle cerebral artery occlusion (MCAO) technique, followed by 22 h of reperfusion. The results of Garcia
test, 2, 3, 5-triphenyltetrazolium chloride (TTC) staining showed that 6 μg/kg and 20 μg/kg E2 replacement induced an
increase in neurological deficit scores, a decrease in the infarct volume and a reduction in the expression of caspase-3
when compared to animals in the OVX group without E2 treatment. However, 50 μg/kg E2 replacement treatment
decreased neurological deficit scores, increased the infarct volume and the expression of caspase-3 when compared
to animals in the control group and 6 up/kg or 20 μg/kg E2 replacement group.
Conclusion: We conclude that physiological levels of E2 exhibit neuroprotective effects on cerebral ischemia; whereas,
pharmacological or supraphysiological doses of E2 have damaging effects on neurons after cerebral ischemia.
Keywords: Estrogen, Neuroprotection, Ischemia, Middle carotid artery occlusion (MCAO), Oxygen and glucose
deprivation (OGD)Background
Substantial research efforts have been made to investigate
the potential beneficial effects of estrogens on incidence
and mortality of stroke. Of these, some studies have shown
a neuroprotective effect of estrogen [1,2], while other
studies have not found beneficial effects of estrogen and* Correspondence: gangwuhou@163.com; mzkxlz@126.com
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reproduction in any medium, provided the orhormone replacement therapy (HRT) [3,4]. The largest
study, the Women’s Health Initiative (WHI), including
more than 16,000 women, was interrupted prematurely
because of findings of an increased risk of coronary heart
disease, breast cancer and stroke associated with estrogen
[4]. Thus, similar clinical studies have been discontinued.
Animal models have been widely applied to elucidate
the effects of estrogens on stroke. Dose and route of
administration of E2 have become one of primary areas of
research focus [5,6]. Several studies have confirmed that. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ma et al. BMC Neuroscience 2013, 14:118 Page 2 of 14
http://www.biomedcentral.com/1471-2202/14/118low physiological dose of E2, which are strikingly similar
to low-basal circulating levels found in cycling animals,
exert profound neuroprotective actions by reducing
apoptosis and enhancing proliferation of newborn
neurons [7,8]. Supraphysiological concentrations (Premarin
1 mg/kg IV, plasma estradiol = 171 ± 51 pg/mL) of E2
administered immediately before the onset of ischemic
injury have also been shown to exert neuroprotection
[9]. Moreover, pharmacological doses (500 and 1000
μg/kg) of E2 effectively protect the brain from ischemic
injury when administered as late as 6 h after the onset of
brain injury [10]. However, in a recent review, a systematic
analysis of 66 studies of effects of estrogens on ischemic
brain damage, indicated that E2 increased neurological
damage. This effect was suggested to be associated with
plasma concentration of pellets with an early, prolonged,
supraphysiological peak of estrogen other than the
method of induction of ischemic brain lesions, the
choice of variables for measurement of outcome, plasma
concentration of estrogens at the time of ischemia, and
characterization of the rat population such as sex, strain,
age, and diseases [6]. Thus, based on these studies, we
aimed to systemically investigate the effects of physio-
logical doses of estradiol (E2) and supraphysiological or
pharmacological doses of E2 on cerebral ischemia both
in vivo and in vitro.
Methods
Experiment design
The experiment was conducted both in vitro and in vivo. In
vitro experiments, PC12 cells were received physiological
and pharmacological doses of estrogen stimulation
[11]. Morphological changes of cells were observed by
light microscopy, and cell proliferation was detected
by Brdu incorporation and flow cytometric analysis.
After PC12 cells were exposed to oxygen and glucose
deprivation (OGD) for 4 hours (h), the cells were
reperfused for 20 h. Cell viability was detected by
MTT assay, cell damage was validated by LDH release
assay, and cell apoptosis was detected by flow cytometric
analysis and western blot. In in vivo experiments, 12
weeks-old female Sprague–Dawley (SD) rats were
ovariectomized (OVX), and following a 10-day recovery
period, the animals were subjected to a daily subcutaneous
injection of different doses of E2 for 4 weeks via an
injection on the back of the neck. The animals were
then subjected to middle carotid artery occlusion (MCAO).
After 2 h of transient occlusion, cerebral blood flow was
restored by removing a nylon suture for 22 h. Finally,
neurological deficits were assessed by the Garcia test, 2,
3, 5-triphenyltetrazolium chloride (TTC) staining was
utilized to evaluate infarct volume. Nissl staining was
used to observe the morphologic neuronal changes in
ischemic penumbra; and western blot was used todetect apoptosis in ischemic penumbra. All reagents were
purchased from Sigma (St Louis, Mo, USA), except those
noted to be purchased from other suppliers.Cell culture
The PC12 cells were plated at a density of 3 × 105cells/
well in a 6-well multiwall plate or 104 cells/well in a
96-well multiwall plate at 37°C under 5% CO2 and 95%
oxygen in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, streptomycin
(100 μg/ml) and penicillin (100 units/mL). The cells
were treated with different concentrations of E2 (Cayman,
America), which were diluted in dimethyl sulfoxide (DMSO)
solution (1:5000). The cells were divided into several groups:
group A: negative control; group B: DMSO; group C: 10 nM
E2; group D: 20 nM E2; group E: 10 μM E2; and group
F: 20 μM E2. After 24 h treatment, the morphology of
the cells in the 6-well multiwall plates was observed and
recorded using an Olympus Microscope (Tokyo, Japan).BrdU incorporation assay
Cell proliferation was determined by immunocytochemical
assessment of BrdU incorporation into replicating DNA of
living cells using the Cellomics BrdU Cell Proliferation
kit (Thermo Fisher Scientific, Pittsburgh, PA). Briefly, the
PC12 cells were plated at a density of 1.5 × 104 cells/well
on glass coverslips in 24-well multiwells and the cells were
incubated with 50 μM Brdu with different concentrations
of E2, as described above. After 24 h incubation, the cells
were fixed with 4% paraformaldehyde for 1 h, followed by
permeabilization and blocking. After washing, the sections
were probed with mouse anti-BrdU primary antibody
(1:500 dilution, Sigma) overnight at 4°C, followed by
FITC-conjugated donkey anti-mouse IgG (1:500 dilution,
Invitrogen) at room temperature for 45 minutes (min) in
the dark. Propidium iodide (PI) dye was used to label all
nuclei. The sections were mounted with 50% glycerol for
examination under a fluorescence microscope.Cell cycle analysis
Cell cycle was assessed by flow cytometry, as previously
described [12]. After 24 h E2 treatment, the cells were
collected by trypsinization, and centrifuged in phosphate
buffered saline (PBS) twice. The cells were then fixed in
pre-cooled 70% ethanol at −20°C, and stained with PI
solution. DNA content was determined by flow cytometry
using CellQuest Software. 10,000 events were counted
for each sample (FACSCalibur, Becton–Dickinson). The
percentage of cells in a particular cell cycle stage was
calculated by the ModFit software (Becton–Dickinson,
USA).
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After 24 h incubation with E2, the cells were washed
twice in d-Hanks buffer and switched to d-Hanks buffer
(OGD medium) with different E2 concentrations. Then
the cells were switched to a modular incubator chamber.
The chamber was flushed with 3 L/min of a 95% N2/5%
CO2 gas mixture for 30 min at room temperature at
3 L/min. The chamber was then sealed and placed in a
37°C container. OGD was carried out for 4 h. Following
the OGD, the cells were incubated with DMEM (without
fetal bovine serum) with different E2 concentrations for
an additional 20 h reperfusion under normal conditions.
Cell viability analysis
After OGD-R, the MTT assay was used to detect cell
viability, as previously described [13]. Briefly, MTT was
dissolved in DMEM, and added to each well for incubation
at a final concentration of 0.5 mg/ml at 37°C for 4 h.
Then, the medium was replaced with 150 μl of DMSO.
The optical density (OD) was recorded on a Universal
Microplate Reader (Elx 800, Bio-TEK instruments Inc.,
USA) at 490 nm. Cell viability was expressed as a percentage
of the control value.
LDH release assay
After OGD-R, cytotoxicity was quantitatively assessed
by measuring the activity of LDH released from the
damaged cells into the culture medium. Briefly, cells
were treated with 0.5% Triton X-100, and the media
which contained detached cells were collected and
centrifuged. The supernatant was used for the assay of
LDH activity. The enzyme activity was determined by using
an assay kit according to the manufacturer’s instructions.
LDH leakage was expressed as the percentage of the
total LDH activity (LDH in the medium + LDH in the
cells), according to the equation LDH released (%) = (LDH
activity in the medium/total LDH activity) × 100. Cultures
under normal conditions (control group) represent basal
LDH release.
Flow cytometric analysis
After OGD-R, cell apoptosis was assayed by flow cytom-
etry, as previously described [14]. Briefly,the cells were
washed with 1 × annexin V-FITC binding buffer prior
to staining with annexin V-FITC and PI for 15 min at
room temperature in the dark. The stained cells were
immediately analyzed using flow cytometry. Apoptotic
and necrotic cells were quantitated by annexin V binding
and PI uptake. The annexin V-FITC+/PI– cell populations
were considered to represent apoptotic cells.
Animals
One hundred and twenty female adult SD rats weighing
200–220 g were obtained from the Laboratory AnimalCenter of the Fourth Military Medical University. The
animals were maintained under a 12:12-h light–dark cycle
and 25°C temperature. The experimental procedures in
this study were approved by the Ethics Committee for
Animal Experimentation of the Fourth Military Medical
University, P. R. China.
OVX and estrogen replacement
The animals were randomly divided into five groups
(n = 24): group A: sham control; group B: rats with
OVX without E2 replacement; group C: rats with
OVX and 6 μg/kg E2 replacement group; group D: rats
with OVX and 20 μg/kg E2 replacement group; and
group E: rats with OVX and 50 μg/kg E2 replacement
group. OVX was adopted by dorsolateral incisions, as
previously described [15]. The animals in the sham
group were subjected to the same operation; however,
their ovaries were kept intact. Five days following OVX,
vaginal smears were taken for 5 days before estrogen
replacement therapy to confirm OVX and cessation of
the estrous cycle [16]. Then these animals received
daily subcutaneous injection of different doses of E2
(diluted in sesame oil solution) on the back of the neck
for four weeks. The dose of estrogen replacement was
based on previous studies [17] and the results of our
pilot study.
MCAO
Four weeks after HRT, MCAO was conducted, as previ-
ously described [18]. The animals within the sham group
were confirmed in diestrus by vaginal smears before
MCAO. After 2 h of transient occlusion, cerebral blood
flow was restored by removing a nylon suture for 22 h.
Physiological parameters included rectal temperature,
blood pressure, heart rate, blood gas, and glucose were
monitored, as previously described [19].
Neurobehavioral evaluation
The neurological deficit was determined according to the
Garcia Test [20], as shown in Additional file 1: Table S1.
Detection of serum estrogen level
The levels of serum estrogen were detected to confirm
HRT. Briefly, after neurological evaluation, the animals
were anesthetized with an overdose of pentobarbital
sodium. The blood was collected from the ophthalmic
artery. Serum estradiol was measured by EIA kit (Cayman
Chemical, Ann Arbor, MI).
Nissl staining
Nissl staining was applied to observe morphologic changes
in cells within the ischemic penumbra after MCAO. After
neurological evaluation, the brains (n = 5) were perfused
with cold 4% paraformaldehyde in 0.01 M phosphate-
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were taken out and cryoprotected in 20% sucrose and 30%
sucrose solution. After the brains were washed in cold
water, 14 μm thick sections were prepared using the Leica
CM1900 frozen slicer. Then the frozen sections were
stained with 0.1% cresyl violet for 20 min, rinsed with
PBS, dehydrated by graded alcohol, transparent by xylene,
and mounted with neutral gum. The sections were
observed using light microscopy.
Assessment of infarct volume
Infarct volume was assessed by TTC staining (n = 13), as
previously described [21]. Briefly, after the blood was
collected, the rats were decapitated. The brain was rapidly
removed and cooled in ice-cold saline for 10 min. Coronal
sections (2 mm) were cut and immersed in 2% TTC at
37°C for 30 min, and then transferred to 4% parafor-
maldehyde in 0.01 M PBS (pH 7.4) for 24 h fixation.
The brain slices were photographed using a digital camera
(Canon ixus 220HS). The unstained areas were defined as
infarcts, and were measured using Photoshop CS3. The
infarct volume was calculated by measuring the unstained
area in each slice, and multiplying the area by the slice
thickness (2 mm). Then the total volume was assessed by
summing the area from all six slices.
Western blot
The expression of pro-apoptotic protein caspase-3 in
PC12 cells and ischemic penumbra (n = 6) was detected
by Western blotting. In brief, soluble lysates of PC12
cells or penumbra were mixed with sample buffer and
NuPAGE reducing agent. Extracted proteins were separated
by 12% SDS-PAGE and were then electrically transferred
to polyvinylidene difluoride membranes. Afterward, the
membranes were blocked in 5% non-fat dry milk diluted
in Tris-buffered saline containing 0.1% Tween 20 for 1 h
at room temperature. Western blots were probed with
rabbit anti-caspase-3 antibodies overnight at 4°C. The
membranes were then incubated with an IRDye secondary
anti-rabbit antibody for 1 h. Protein bands were visualized
using the LI-COR Odyssey System.
Statistical analysis
Data are presented as means ± SEMs. Differences among
the groups were analyzed by one way ANOVA. Differences
between two groups were analyzed by two-tailed Student’s
t-test with SPSS 11.5. A P-value of < 0.05 was considered
statistically significant.
Results
Physiological dose of E2 promote cell proliferation but
pharmacological dose of E2 inhibite cell proliferation
The effects of different doses of E2 on cell morphology
and cell proliferation were observed using light microscopy.When compared with the control and DMSO group,
treatment of PC12 cells with 10 nM or 20 nM E2
exhibited a marked increase in the number of cells;
however, no significant morphological changes of the
cells were observed (Figure 1). By contrast, incubation
of 10 μM or 20 μM E2 induced a marked decrease in
the number of cells, and the majority of cells lost their
neuritis and appeared round (Figure 1).
The results of cell proliferation were further confirmed
by BrdU incorporation assay and flow cytometric analysis.
As shown in Figure 2, the ratio of BrdU-positive cells
in the control and DMSO groups were 64.3% ± 4.2%
and 61.6% ± 5.4%, respectively. 10 nM and 20 nM E2
induced an increase in the ratio of Brdu-positive cells
to 78.1% ± 6.1% and 76.6% ± 5.3%, respectively (*p < 0.01
v.s. the control and DMSO groups). However, the ratio
of BrdU-positive cells in the 10 μM and 20 μM E2
group decreased to 48.3% ±3.1% and 41.7% ±3.7%,
respectively (#p < 0.05 v.s. the control and DIMSO groups).
The results of flow cytometric analysis were consistent
with the Brdu incorporation assay. As shown in Figure 3,
the percentage of cells in S phase in the control and
DMSO groups were 21.4% ± 1.2% and 20.1% ± 1.6%,
respectively. 10 nM and 20 nM E2 treatment induced a
slightly increase in the percentage of the cells in the S
phase to 24.5% ± 1.7% and 24.9% ± 1.9%, respectively,
however, no significant difference was observed when
compared with those in the control and DMSO groups.
Whereas treatment of 10 μM and 20 μM E2 induced a
marked decrease in the percentage of the cells in S phase
to 14.6% ± 1.0% and 12.5% ± 0.9%, respectively (# p < 0.05
v.s. the control and DMSO group).
In the control and DMSO groups, the percentage of
cells in S + G2 phase was 66.3% ± 1.7% and 62.6% ±1.9%,
respectively. 10 nM and 20 nM E2 treatment increased
the percentage of cells in S + G2 phase to 78.9% ± 5.0%
and 75.3% ± 4.8%, respectively (*p < 0.01 v.s. the control
and DIMSO group). By contrast, 10 μM and 20 μM E2
treatment decreased the percentage of cells in S + G2
phase to 46.8% ± 2.9% and 42.3% ± 2.7%, respectively
(# p < 0.05 v.s. control and DMSO group).
Physiological doses of E2 attenuate cell damage but
pharmacological doses of E2 aggregated cell damage
The MTT assay was used to test the effects of E2 on
cell viability after exposure to OGD-R (Figure 4A). The
cell viability in the control group was considered as
100%. ± 5.9%, the cell viability in the DMSO group was
97.6% ± 4.2%. Pre-treatment with 10 nM or 20 nM E2
increased the cell viability by 14.2.8% ± 0.5% and 23.1 ±
5.1%, respectively (*p < 0.01 v.s. the DMSO group). By
contrast, pre-treatment with 10 μM or 20 μM E2
decreased the cell viability by 8% ± 2.5% and 12% ± 1.2%
(# p < 0.05 v.s. DMSO group), respectively.
Figure 1 The effects of different doses of E2 on cultured PC12 cell morphology. PC12 cells treated with 10 nM or 20 nM E2 exhibited a
marked increase in cell number. PC12 cells treated with 10 μM or 20 μM E2 (especially in the 20 μM group) exhibited a marked decrease in cell
number with most cells losing their neurites and appearing round. Scale bar = 100 μM.
Ma et al. BMC Neuroscience 2013, 14:118 Page 5 of 14
http://www.biomedcentral.com/1471-2202/14/118LDH release assay was used to evaluate the effects of
E2 on cell necrosis after the cells were exposed to
OGD-R (Figure 4B). The level of LDH release in the
control group was set as 100% ± 4.7%. The DMSO group
was 104.8% ± 4.6%. Results revealed that treatment of
10 nM and 20 nM E2 slightly decreased the level of
LDH release to 93.3% ± 5.4% and 90.8 ± 5.1%, respectively.
By contrast, 10 μM and 20 μM E2 slightly increased the
level of LDH release to 108.1% ± 5.7% and 114.2% ±
3.8%, respectively. However, no significant difference
was observed among different doses of E2 treatments
and the control and DMSO groups.
Flow cytometric analysis was used to test the effect of
E2 on cell apoptosis after the cells were exposed to
OGD-R (Figure 5). The apoptotic index of the control
and DMSO group were 9.7% ± 2.3% and 9.2% ± 1.9%,
respectively. Pre-treatment with 10 nM or 20 nM E2
attenuated OGD-R-induced cell apoptosis to 4.2% ±
1.5% and 4.5% ± 1.3%, respectively (*p < 0.01 v.s. the
control and DMSO groups). Conversely, pre-treatment
with 10 μM or 20 μM E2 increased OGD-R-induced ap
optosis to 16.6% ± 2.5% and 18.9% ± 2.9% (#p < 0.05
vs. the control and DMSO groups).
Physiological doses of E2 replacement exhibit
neuroprotective effects, supraphysiological doses of E2
replacement induced neurodamage
The OVX and estrous cycle were confirmed by vaginal
smears as shown in Additional file 1: Figure S1. All rats
demonstrated diestrous vaginal smears prior to estradioltreatment, indicating that successful OVX and cessation
of the estrous cycle was achieved. Prior to MCAO, the
rats in the control group were also confirmed to be on
diestrous (Additional file 1: Figure S1).
The OVX and estrogen replacement were further vali-
dated by detection of serum estrogen levels. As shown in
Additional file 1: Figure S2, the levels of serum estrogen in
the control group (19.5 ± 2.5 pg/ml) further indicated that
the rats were on diestrous. The level of serum estrogen in
OVX group (9.3 ± 1.9 pg/ml) was significantly lower than
that in the control group. Compared with the upper limit
of serum estrogen level in normal adult rat, the levels of
serum estrogen in the rats with 6 μg/kg (17.2 ± 2.7 pg/ml),
20 μg/kg (59.8 ± 12.1 pg/ml) and 50 μg/kg (127.7 ± 25.5
pg/ml) E2 replacement groups successfully mimic relative
low, high and supraphysiological level of E2, respectively.
All animals survived 22 h after reperfusion. Physiological
parameters of the animals during the MCAO period
are summarized in Additional file 1: Table S2. Rectal
temperature, blood pressure, heart rate, blood gas, and
glucose were remained in the normal range. No significant
differences in physiological parameters were observed
among groups.
To evaluate the neuroprotective effect of different doses
of E2 against ischemia–reperfusion injury induced by
the MCAO, we performed neurological deficit score
test, assessment of infarct volume and Nissl staining. As
shown in Figure 6, the OVX group revealed significant
lower neurological deficit score compared to the control
group (** p <0.001). Treatment with 6 μg/kg or 20 μg/kg
Figure 2 The effects of different doses of E2 on cultured PC12 cell proliferation assessed by Brdu incorporation assay. (A) The triangle
represents the nuclei labeled by PI dye (Red), and the arrow represents the replicating DNA by BrdU incorporation (Green). (B) The ratio of
Brdu-positive cells in 10 nM and 20 nM E2 groups significantly increased (*p < 0.01, compared with the control and DMSO groups), and the
Brdu-positive cells in 10 μM and 20 μM E2 group markedly decreased (#p < 0.05, v.s. the control and DMSO groups).
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compared to the OVX group (#p < 0.05 ), suggesting
that 6 μg/kg or 20 μg/kg E2 nearly reversed the effects
of OVX on neurological deficits induced by MCAO. By
contrast, treatment with 50 μg/kg E2 significantly decreased
the neurological deficit scores when compared with
that in the control group and 6 μg/kg or 20 μg/kg E2
groups (*p < 0.01), however, no statistical significance was
observed when compared to the OVX group.
As shown in Figure 7, the infarct volume in the control
group was 10.5% ±1.8%. OVX increased the infarct
volume to 38.4% ± 3.6% (**p < 0.01 vs. the control group).
Treatment with 6 μg/kg or 20 μg/kg E2 significantly
decreased the infarct volume to 15.6% ± 2.4% and
20.3% ± 2.7%, respectively (# p < 0.05 vs. the OVX group),indicating that 6 μg/kg or 20 μg/kg E2 weakened the
effects of OVX. However, treatment with 50 μg/kg E2
significantly increased the infarct volume to 35.8% ± 3.2%
(*p < 0.05 v.s. the control group and 6 μg/kg or 20 μg/kg
E2 replacement group). However, no significant difference
was found when compared to the OVX group.
To exam neuronal damage in ischemic penumbra after
MCAO, Nissl staining was performed. We found that the
injured neurons showed shrunken cell bodies ac companied
by shrunken and pyknotic nuclei. The number of injured
neurons in OVX group was significantly more than control
group (**p < 0.01; Figure 8). Treatment with 6 μg/kg or
20 μg/kg E2 significantly reduced neuronal damage and
preserved morphology (#p < 0.05 v.s. OVX group).
However, treatment with 50 μg/kg E2 significantly induced
Figure 3 Effects of different doses of E2 on cell proliferation of cultured PC12 by flow cytometric analysis. (A) The first red peak, the
arc-shaped hatched portion in the middle and the second red peak represent G1 phase, S phase and G2 phase of cell cycle, respectively. (B) 10 nM
and 20 nM E2 treatment did not induce a significant increase in the percentage of the S phase cells of the cell cycle, but induced a significant increase
in the percentage of cells in S + G2 phase. 10 μM and 20 μM E2 treatments significantly decreased the percentage of cells in both S phase and S + G2
phase of the cell cycle (*p < 0.01 v.s. the control and DMSO groups, #p < 0.05 v.s. the control and DMSO groups). Dip: diploid.
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Figure 4 The effects of different doses of E2 pre-treatment on PC12 cell viability and cell damage. (A) MTT assay was used to test the cell
viability after OGD-R. 10 nM and 20 nM E2 significantly promoted the cell viability. The cell viability in the cells treated with 10 μM and 20 μM E2
group significantly decreased. (*p < 0.01 compared with the control and DMSO groups, #p < 0.05 compared with the control and DMSO groups).
(B) LDH release assay was used to detect cell necrosis after OGD-R. 10 nM and 20 nM E2 did not significantly attenuate LDH release; and 10 μM
and 20 μM E2 the LDH release in group had not markedly declined (v.s. the control and DMSO groups).
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μg/kg or 20 μg/kg E2 replacement group).Physiological doses of E2 reduced the expression of
caspase-3, supraphysiological doses of E2 increased the
the expression of caspase-3
Western blot was used to explore the mechanism under-
lying the effects of different doses E2 on ischemia. As
shown in Figure 9 (A), pre-treatment with 10 nM or 20 nM
E2 significantly attenuated OGD-R-induced the expression
of pro-apoptotic protein caspase-3 when compared with
DMSO group (*p < 0.05). Conversely, pre-treatment with
10 μM or 20 μM E2 increased the expression of caspase-3
(*p < 0.05, **p < 0.01, v.s. DMSO group). As shown in
Figure 9 (B), OVX significantly increased the expression of
caspase-3 in ischemic penumbra compared with control
group (**p < 0.01). Treatment with 6 μg/kg or 20 μg/kg
E2 significantly reduced the expression of caspase-3 when
compared with the OVX group (#p < 0.05). However,
treatment with 50 μg/kg E2 significantly increased the
expression of caspase-3 compared with the control
group and 6 μg/kg or 20 μg/kg E2 replacement group
(**p < 0.01).Discussion
Neuroprotective effects of E2 have been debated for
decades [1-4]. Among these, the doses, duration, route
and period of estrogen replacement have become the
most important parameters. In this study, we demonstrated
that in vitro physiological doses of E2 promoted cell
proliferation and attenuated cell damage; where zas
pharmacological doses of E2 inhibited cell proliferation
and promoted cell damage. In vivo experiments further
demonstrated that physiological levels of E2 replacement
exhibited neuroprotective effects and supraphysiological
levels of E2 replacement promoted neurodamage.Previous reports have demonstrated that estrogen can
regulate the development, maturation, survival, and function
of multiple types of neurons in different brain regions [22].
However, it is unclear whether the effects of physiological
doses of E2 and pharmacological doses of E2 exert different
effects on nerve cells. Interestingly, we observed that
physiological doses of E2 (10 nM and 20 nM) increased
the number of PC12 cells, however, pharmacological
doses of E2 (10 μM and 20 μM) decreased the number
of cells and induced the cells to lose their neurites.
Mechanisms underlying this phenomenon is unclear.
Previous research has reported that 0.5 nM E2 was
ineffective in promoting proliferation of human neural
progenitor cell (hNPC), as assessed by BrdU incorporation.
Minimal effectiveness of E2 to promote proliferation
was shown at 1 nM, maximal effectiveness at 100 nM and
decrement at 250 nM, suggesting that the efficacy of E2
on proliferation was dose dependent [23]. However, the
effect of pharmacological doses of E2 on the proliferation
of nerve cells has been rarely studied. To explore this
question, PC12 cells received different concentrations
E2 stimulus. The results of immunocytochemistry dem-
onstrated that physiological doses of E2 could promote
cell proliferation, which was consistent with previous
findings [23]. Additionally, Suzuki et al. [24] has shown
that physiological low doses of E2 protected neurons
from brain ischemic injury by enhancing proliferation
of newborn neurons. More importantly, our results have
demonstrated, for the first time, that pharmacological
doses of E2 inhibited the proliferation of nerve cells.
It is known that cell proliferation is determined by the
DNA replication during the cell cycle, thus, flow cytometric
analysis was used to detect the effects of E2 on the cell
cycle. The results revealed that physiological doses of
E2 significantly increased the percentage of cells in S + G2
phase of the cell cycle; however, pharmacological doses
of E2 markedly decreased percentage of cell in S phase
Figure 5 The effects of different doses of E2 pre-treatment on apoptosis of PC12 cell after OGD-R as assessed by flow cytometric
analysis. (A) The cell populations of annexin V-FITC+/PI–(Quadrant 4) were considered to represent apoptotic cells. The cell apoptosis rate in the
control, DMSO, 10 nM, 20 nM, 10 μM and 20 μM groups is 9.8%, 9.4%, 3.9%, 4.4%, 16.9% and 18.7%, respectively. (B) The cell apoptosis rate in 10
nM and 20 nM E2 group significantly decreased. And the cell apoptosis rate of 10 μM and 20 μM E2 group significantly increased (* p < 0.01 v.s.
the control and DMSO groups, #p < 0.05 v.s. the control and DMSO groups).
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been shown to increase the expression of PCNA and
CDK1/cdc2 in hNPCs [23], PCNA and CDK1/cdc2 are
well defined and commonly used as markers of cell cycle.
PCNA is a marker of the cells in early G1 phase and S
phase of the cell cycle, and it acts as a homotrimer toincrease the processing of leading strand synthesis during
DNA replication [25]. Whereas CDK1 exists as a compo-
nent of CDK1/cyclin B complex, is required for transition
from G2 to M phase [26]. Taken together, we conclude
that physiological doses of E2 promote DNA replication
by acting on the PCNA and CDK1/cdc2 complexes. By
Figure 6 Neurological behavior score. The Garcia Test was
applied to determine the neurological deficit in the rats receiving
ischemia–reperfusion injury by MCAO in animals receiving different
doses of E2. The OVX group demonstrated significantly lower
neurological deficit scores than the control group. Treatment with
6 μg/kg or 20 μg/kg E2 significantly improved the neurological
deficit scores. Treatment with 50 μg/kg E2 resulted in significantly
lower neurological deficit scores (*p < 0.01 v.s. the control group,
# p < 0.05 v.s. the OVX group).
Figure 7 The infarct volume in rats exposed to ischemia–
reperfusion injury by MCAO receiving different doses of E2.
(A) The OVX group resulted in larger infarct volume compared to the
control group. 6 μg/kg and 20 μg/kg E2 replacement significantly
decreased the infarct volume. 50 μg/kg E2 replacement group resulted
in larger infarct volume than the control group and 6 μg/kg or 20 μg/
kg E2 replacement group. (**p < 0.01 v.s. the control group, #p < 0.05
v.s. the OVX group, *p < 0.05 v.s. the control group and 6 μg/kg or 20
μg/kg E2 replacement group). (B) Representative photographs
showing infarct volume in the different groups after the MACO.
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attenuate DNA replication, however, the mechanism is
still unclear.
To further investigate the effects of E2 on nerve cells
after nerve injury, we applied an OGD-R experimental
paradigm. OGD-R is composed of a hypoxic and a reoxy-
genation/reperfusion phase and it is recognized as an
ideal in vitro model for the ischemic stroke. Our results
demonstrated that physiological doses of E2 significantly
increased cell apoptosis induced by OGD-R. Whereas
pharmacological doses of E2 markedly attenuated cell
apoptosis. Previous study have shown that 100 nM E2
was found to have a neuroprotective effect against
CoCl2-induced apoptosis in PC12 cells by attenuating
ROS production and modulating apoptotic signal pathway
through caspase cascades, Bcl-2 family, cytochrome c,
Fas/Fas-L as well as PI3K/Akt pathway [27]. Studies have
reported that chronic E2 treatment could rescue neurons
destined to apoptosis or necrosis by interfering with
apoptotic death cascades that activate caspase-3 [28].
Our results demonstrated that physiological doses of E2
significantly reduced the expression of pro-apoptotic
protein caspase-3, however, pharmacological doses of
E2 increased the expression of caspase-3. These results
verified that physiological doses of E2 exhibit the neuro-
protective effects by modulating apoptotic signal pathway,
whereas pharmacological doses of E2 may inhibit the
pathway, but the mechanism need to be further explored.
We further examined the effects of different levels of
E2 replacement in vivo on OVX rats following MCAO.
We found that estrogens used in all previous studies
of the neurodamaging effects of E2 were commerciallymanufactured slow-release pellets, which created an early,
prolonged, supraphysiological peak plasma concentration
[6]. Therefore, we executed hormone replacement by daily
subcutaneous injection of E2 on the back of the neck of
the rats for 4 weeks, resulting in the tailored serum E2
level. The result showed that physiological levels of E2
replacement significantly improved neurological deficit
scores, decreased infarct volume, reduced neuronal damage
and inhibited the apoptosis in ischemic penumbra. How-
ever, superphysiological levels of E2 replacement worsen
the ischemia–reperfusion injury by significantly lowering
neurological deficit scores, increasing infarct volume,
inducing neuronal damage and promoting the apoptosis
in ischemic penumbra. Several studies [7,8] have con-
firmed that low physiological levels of E2, which are
strikingly similar to low-basal circulating levels found in
cycling animals, exert profound neuroprotective actions
by reducing apoptosis, enhancing proliferation of newborn
Figure 8 Nissl staining showed the morphologic changes of neurons in the ischemic penumbra after MCAO. (A) Representative
photographs showing neuronal damage in the ischemic penumbra after MCAO. (B) The number of injured neurons in the OVX group was
significantly more than that in the control group (**p < 0.01). Treatment with 6 μg/kg or 20 μg/kg E2 significantly reduced neuronal damage and
preserved morphology (#p < 0.05, v.s. OVX group). However, treatment with 50 μg/kg E2 significantly induced neuronal damage (**p < 0.05 v.s.
the control group and 6 μg/kg or 20 μg/kg E2 replacement group). Scale bar: 20 μm.
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pellets, lower doses of estrogen tended to decrease ischemic
damage, whereas higher doses tended to increase the
damage [6]. Furthermore, a recent study [29] showed
that injection of estrogens into adult OVX female rats
30 mins before conditioning, the low physiological doses
of 17β-estradiol and 17a-estradiol enhanced, whereas
the superphysiological doses of 17β-estradiol and 17a-
estradiol impaired, contextual fear conditioning, which
relies on the integrity of the hippocampus and amygdala.
Nevertheless, some studies have shown neuroprotective
effects of supraphysiological or pharmacological levels
of E2. It has been shown that supraphysiological or
pharmacological levels of E2 administered immediately
before the onset [9], or as late as 6 h after the onset
[10], of ischemic injury effectively protected the brainagainst ischemic injury. It appears that supraphysiological
or pharmacological levels of E2 have both neuroprotective
effects and neurodamaging effects depending on the
timing of E2 administration. These studies [9,10] reported
that acutely administration of E2 but not long-term E2
replacement produced the neuroprotective effects of
supraphysiological or pharmacological doses of E2. It is
known that estradiol acts through different estrogen
receptors (ERs) and activates distinct secondary mes-
senger pathways at different time courses and involves
various downstream mechanisms [30]. In the classical
chronic genomic mechanism, estradiol acts through
soluble intracellular α or β receptors (ERα or ERβ), once
these receptors were activated, they translocate to the
nucleus where they function as ligand-dependent tran-
scription factors [31]. In contrast, fast non-genomic effects
Figure 9 The expression of pro-caspase protein casepase-3 in PC12 cells and ischemic penumbra. (A) Pre-treatment with 10 nM or 20 nM
E2 significantly attenuated OGD-R-induced the expression of pro-apoptotic protein caspase-3 (*p <0.05, v.s. DMSO group). Pre-treatment with 10
μM or 20 μM E2 increased the expression of caspase-3 (*p < 0.05, **p < 0.01, v.s. DMSO group). (B) OVX significantly increased the expression of
caspase-3 in the ischemic penumbra (**p < 0.01, v.s. the control group). Treatment with 6 μg/kg or 20 μg/kg E2 significantly reduced the
expression of caspase-3 (# p < 0.05, v.s. the OVX group). Treatment with 50 μg/kg E2 significantly increased the expression of caspase-3
(**p < 0.01, v.s. control group and 6 μg/kg or 20 μg/kg E2 replacement group).
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specific G-protein–coupled receptors (GPR30 and ER-X)
that regulate ligand-gated ion channels and neurotransmit-
ter transporters [32]. The GPR30 receptor is reported
to be a novel estrogen receptor uniquely localized to the
endoplasmic reticulum [33] and may act together with
intracellular estrogen receptors to activate cell-signaling
pathways to promote neuron survival after global ischemia
[34,35]. In a culture of cortical neurons, treatment with
the GPR30 agonist G1 for 45 min attenuated the
excitotoxicity induced by NMDA exposure. Additionally,
acute neuroprotection mediated by GPR30 is dependent
on rapid G-protein–coupled signals and ERK1/2 activation
but independent of transcription or translation [36].
Moreover, acute estradiol treatment protects CA1 neurons
from ischemia-induced apoptotic cell death via the PI3K/
Akt pathway [37]. Therefore, the acute neuroprotective
effects of estrogen maybe mediated via the fast non-
genomic mechanism. Our results indicated that chronic
supraphysiological doses of E2 replacement may exert
neuroprodamaging effects, but during acute treatment for
ischemic stroke, the supraphysiological or pharmacological
doses of E2 may exert neuroprotective effects.
It is worthwhile to note several limitations in this study.
First, we had not thoroughly investgate the molecular
mechanisms underlying the effects of different doses of E2
on cell morphology, cell proliferation and cell apoptosis.
Further studies are warranted to elucidate the mechanisms
underlying the attenuation of cell proliferation and increase
in cell apoptosis induced by pharmacological doses of E2.
Second, the latest study has accurately demonstrated that
E2 level in the hippocampus is approximately 8 nM in the
male and 0.5–2 nM in the female, which is much higher
than that in the circulation [38]. This hippocampus-derived
estrogen rapidly modulates dendritic spines [39], which hasbeen extensively studied in relation to memory processes
and synaptic plasticity. Therefore, the effects of estrogen
replacement on the changes of estrogen level in the
hippocampus should be further studied.
Conclusion
Taken together, physiological levels of E2 exhibit powerful
neuroprotective actions both in vivo and in vitro, and these
protective actions involve induction of cell proliferation and
attenuation of neuronal apoptosis in response to ischemic
brain injury. Our results also demonstrated that the supra-
physiological levels of E2 attenuate neuroprotective actions
in vivo. In vitro experiments demonstrated that high-
dose E2 showed neurodamaging effects by attenuating
cell proliferation and increasing cell apoptosis. These
results may provide a therapeutic basis for clinicians to
treat menopausal or ovariectomized women with estrogen
replacement therapy.
Additional file
Additional file 1: Figures S1. Verification of OVX. The effects of OVX
and the estrous stage were determined by cytological evaluations of
vaginal smears under microscopic examination. The smears of rats in the
control group consisted almost exclusively of leukocytes, indicating the
rats were at diestrus. The smears of OVX rats also consisted of leukocytes,
indicating the rats were also at diestrus, but the number of leukocytes
was significantly fewer than that in the control group. Figures S2. The
levels of serum estrogen were detected to confirm the HRT. After
neurological evaluation, the blood was collected from the ophthalmic
artery of the rats. Serum estradiol was measured by EIA kit in the control
group, the OVX group, 6 μg/kg, 20 μg/kg and 50 μg/kg E2 replacement
groups. the level of serum estradiol at 18.3 ± 0.7 pg/ml, 57.8 ± 8.1 pg/ml
and 127.3 ± 10.4 pg/ml, which were roughly equivalent to low, high and
supra physiological levels of E2. These results confirmed that HRT had
achieved the desired effect. Table S1. Neurolgical evaluation after the
middle cerebral artery occlusion in Wister rats. Table S2. The
physiological parameters in animals of different groups before, during
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http://www.biomedcentral.com/1471-2202/14/118and after the MCAO. The physiological parameters of OVX, 6 μg/kg,
20 μg/kg and 50 μg/kg E2 group had no significant difference compared
to the control group (p > 0.05).
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